ATE407143T1 - Fusionsprotein des regulatorische/akzessorische hiv proteine - Google Patents

Fusionsprotein des regulatorische/akzessorische hiv proteine

Info

Publication number
ATE407143T1
ATE407143T1 AT05017695T AT05017695T ATE407143T1 AT E407143 T1 ATE407143 T1 AT E407143T1 AT 05017695 T AT05017695 T AT 05017695T AT 05017695 T AT05017695 T AT 05017695T AT E407143 T1 ATE407143 T1 AT E407143T1
Authority
AT
Austria
Prior art keywords
proteins
fusion protein
nucleic acids
regulatory
hiv proteins
Prior art date
Application number
AT05017695T
Other languages
English (en)
Inventor
Paul Howley
Sonja Leyrer
Eva Felder
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of ATE407143T1 publication Critical patent/ATE407143T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05017695T 2002-05-16 2003-05-14 Fusionsprotein des regulatorische/akzessorische hiv proteine ATE407143T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200200754 2002-05-16

Publications (1)

Publication Number Publication Date
ATE407143T1 true ATE407143T1 (de) 2008-09-15

Family

ID=29433046

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03730029T ATE310016T1 (de) 2002-05-16 2003-05-14 Fusionsprotein regulatorischer/akzessorischer hiv-proteine
AT05017695T ATE407143T1 (de) 2002-05-16 2003-05-14 Fusionsprotein des regulatorische/akzessorische hiv proteine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03730029T ATE310016T1 (de) 2002-05-16 2003-05-14 Fusionsprotein regulatorischer/akzessorischer hiv-proteine

Country Status (23)

Country Link
US (7) US20050222388A1 (de)
EP (2) EP1506223B1 (de)
JP (3) JP2006502704A (de)
KR (4) KR101196178B1 (de)
CN (3) CN1325512C (de)
AT (2) ATE310016T1 (de)
AU (2) AU2003240638B2 (de)
BR (1) BR0309963A (de)
CA (1) CA2483640A1 (de)
CY (1) CY1108638T1 (de)
DE (2) DE60302356T2 (de)
DK (2) DK1506223T3 (de)
EA (1) EA007154B1 (de)
ES (2) ES2253675T3 (de)
IL (3) IL164178A0 (de)
MX (1) MXPA04010683A (de)
NO (1) NO20045229L (de)
NZ (2) NZ556144A (de)
PL (2) PL372092A1 (de)
PT (1) PT1652857E (de)
SI (2) SI1506223T1 (de)
UA (3) UA82998C2 (de)
WO (1) WO2003097675A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
UA82998C2 (ru) * 2002-05-16 2008-06-10 Бавариан Нордик А/С Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
ATE520708T1 (de) 2003-03-28 2011-09-15 Us Gov Health & Human Serv Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung
IL296832A (en) * 2005-10-18 2022-11-01 Nat Jewish Health Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin
EP2044198A4 (de) 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc Chimärische influenza-virus-ähnliche partikel
CA2657955A1 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
SG10201803982TA (en) 2008-05-16 2018-07-30 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
SG193145A1 (en) 2008-07-21 2013-09-30 Taiga Biotechnologies Inc Differentiated anucleated cells and method for preparing the same
DK3339321T3 (da) 2008-08-28 2021-06-21 Taiga Biotechnologies Inc Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
AU2010305030A1 (en) 2009-10-08 2012-05-10 Bavarian Nordic A/S Generation of a broad T-cell response in humans against HIV
WO2011043830A2 (en) * 2009-10-09 2011-04-14 New York University Methods, agents and peptides for inducing an innate immune response in hiv vaccination
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
EP2620446A1 (de) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogene zur HIV-Impfung
US9789135B2 (en) 2012-07-20 2017-10-17 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
WO2015192339A1 (zh) * 2014-06-18 2015-12-23 中山大学 一种嵌合载体及其制备方法和应用
CN104130331B (zh) * 2014-06-19 2017-06-06 中山大学 一种抗hiv‑1病毒药物及其制备和应用
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN105330729A (zh) * 2015-11-18 2016-02-17 南京医科大学 一种人类免疫缺陷病毒Vpr蛋白的制备方法
EP3548425B1 (de) 2016-12-02 2023-03-29 Taiga Biotechnologies, Inc. Nanopartikelformulierungen
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
EP3969041A4 (de) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. Zusammensetzungen und verfahren zur behandlung von t-zell-erschöpfung
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4088697A (en) * 1996-08-26 1998-03-19 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
IT1297090B1 (it) 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
FR2773156B1 (fr) * 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
FI105105B (fi) 1998-02-27 2000-06-15 Finnish Immunotechnology Ltd O Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
BR0107972A (pt) 2000-01-31 2002-11-05 Smithkline Beecham Biologicals Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
EP2388015A1 (de) * 2000-03-02 2011-11-23 Emory University DNA-Expressionsvektoren und Verwendungsverfahren
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
KR100815888B1 (ko) * 2000-07-14 2008-03-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｈｉｖ 보조 단백질을 암호화하는 ｄｎａ 백신
US20040241140A1 (en) * 2000-11-01 2004-12-02 Pavlakis George N. Expression vectors able to elicit improved immune response and methods of using same
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
UA82998C2 (ru) * 2002-05-16 2008-06-10 Бавариан Нордик А/С Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті

Also Published As

Publication number Publication date
KR20050010000A (ko) 2005-01-26
ATE310016T1 (de) 2005-12-15
CN1982332A (zh) 2007-06-20
AU2003240638B2 (en) 2008-05-15
DK1506223T3 (da) 2006-04-10
US20120142097A1 (en) 2012-06-07
US8143054B2 (en) 2012-03-27
UA85373C2 (ru) 2009-01-26
UA92788C2 (ru) 2010-12-10
ES2313166T3 (es) 2009-03-01
KR101196178B1 (ko) 2012-11-01
EA007154B1 (ru) 2006-08-25
US8389275B2 (en) 2013-03-05
BR0309963A (pt) 2005-02-22
EP1652857B9 (de) 2009-10-14
EA200401504A1 (ru) 2005-04-28
AU2003240638A1 (en) 2003-12-02
US20090280561A1 (en) 2009-11-12
CN1653085A (zh) 2005-08-10
PL372092A1 (en) 2005-07-11
WO2003097675A1 (en) 2003-11-27
US20050222388A1 (en) 2005-10-06
DE60323407D1 (de) 2008-10-16
US8137931B2 (en) 2012-03-20
PL397252A1 (pl) 2012-04-10
KR20120106894A (ko) 2012-09-26
PT1652857E (pt) 2008-12-12
DE60302356D1 (de) 2005-12-22
EP1652857A3 (de) 2007-03-14
KR20110099058A (ko) 2011-09-05
ES2253675T3 (es) 2006-06-01
NO20045229L (no) 2004-11-29
KR100996330B1 (ko) 2010-11-23
SI1506223T1 (sl) 2006-04-30
EP1652857B1 (de) 2008-09-03
AU2008252074B2 (en) 2012-02-16
JP2010099084A (ja) 2010-05-06
US20100047871A1 (en) 2010-02-25
EP1506223B1 (de) 2005-11-16
CN101108882A (zh) 2008-01-23
IL164178A (en) 2011-01-31
CA2483640A1 (en) 2003-11-27
US8147839B2 (en) 2012-04-03
HK1076822A1 (en) 2006-01-27
IL164178A0 (en) 2005-12-18
JP2006502704A (ja) 2006-01-26
JP2009178165A (ja) 2009-08-13
US20100047268A1 (en) 2010-02-25
US20060257974A1 (en) 2006-11-16
US7569228B2 (en) 2009-08-04
US8435535B2 (en) 2013-05-07
IL197304A0 (en) 2011-07-31
EP1506223A1 (de) 2005-02-16
UA82998C2 (ru) 2008-06-10
NZ556144A (en) 2008-04-30
MXPA04010683A (es) 2005-02-17
CY1108638T1 (el) 2014-04-09
DE60302356T2 (de) 2006-08-03
NZ536499A (en) 2008-04-30
KR20100063126A (ko) 2010-06-10
SI1652857T1 (sl) 2009-02-28
US20120142096A1 (en) 2012-06-07
DK1652857T3 (da) 2009-01-05
AU2008252074A1 (en) 2009-01-08
CN1325512C (zh) 2007-07-11
EP1652857A2 (de) 2006-05-03

Similar Documents

Publication Publication Date Title
IL197304A0 (en) Fusion protein of hiv regulatory/accessory proteins
IL264925A (en) Isolated or recombinant proteins that induce an immune response against S. PYOGENES, preparations containing them and their uses
ECSP093601A (es) Proteínas derivadas del virus del síndrome de mancha blanca y sus usos
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
DK1093517T3 (da) Neisseria-meningitidis-antigener og præparater
ATE540575T1 (de) Regulatoren des zucker- und lipidstoffwechsels in pflanzen
EP1548032A4 (de) Kdr-peptide und diese enthaltende impfstoffe
MX9200709A (es) Activacion mejorada de proteinas recombinadas. activacion mejorada de proteinas recombinadas.
DE60320362D1 (de) Verfahren zur Herstellung von Dipeptiden
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
DE60335726D1 (de) Chromoprotein und fluoroproteine
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
JOP20250211A1 (ar) بروتينات الاندماج الثلاثية لـ rsv المستقرة بدون مجال تثليث متغاير
ATE469170T1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
ATE503834T1 (de) Bibliotheken rekombinanter chimärischer proteine
ATE447008T1 (de) Rre und cte umfassende gentechnische konstrukte und zusammensetzungen und verwendungen davon
WO2005047483A3 (en) Renta: an hiv immunogen and uses thereof
WO2008039983A3 (en) Methods and compositions using mutant gp120
CY1113749T1 (el) Συνθεσεις εμβολιων dna και μεθοδοι χρησης τους

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1652857

Country of ref document: EP